A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
August 7, 2017
End Date
January 4, 2018
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
August 7, 2017
End Date
January 4, 2018